These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25176167)

  • 21. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
    Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Abarca JE; Herrera-Guzmán D; Montelongo-Pedraza P; Padrós Blázquez F; Peró-Cebollero M; Guàrdia-Olmos J
    J Affect Disord; 2010 Jun; 123(1-3):341-50. PubMed ID: 19896719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder.
    Mamdani F; Berlim MT; Beaulieu MM; Turecki G
    World J Biol Psychiatry; 2014 Feb; 15(2):135-44. PubMed ID: 23530732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome.
    Howland RH; Rush AJ; Wisniewski SR; Trivedi MH; Warden D; Fava M; Davis LL; Balasubramani GK; McGrath PJ; Berman SR
    Drug Alcohol Depend; 2009 Jan; 99(1-3):248-60. PubMed ID: 18986774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study.
    Daly EJ; Trivedi MH; Fava M; Shelton R; Wisniewski SR; Morris DW; Stegman D; Preskorn SH; Rush AJ
    J Clin Psychopharmacol; 2011 Feb; 31(1):31-8. PubMed ID: 21192140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in plasma and platelet BDNF levels induced by S-citalopram in major depression.
    Serra-Millàs M; López-Vílchez I; Navarro V; Galán AM; Escolar G; Penadés R; Catalán R; Fañanás L; Arias B; Gastó C
    Psychopharmacology (Berl); 2011 Jul; 216(1):1-8. PubMed ID: 21308467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depression.
    Bschor T; Uhr M; Baethge C; Lewitzka U; Ising M; Erbe S; Winkelmann P; Ritter D
    J Clin Psychopharmacol; 2013 Feb; 33(1):38-44. PubMed ID: 23277245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.
    Hu XZ; Rush AJ; Charney D; Wilson AF; Sorant AJ; Papanicolaou GJ; Fava M; Trivedi MH; Wisniewski SR; Laje G; Paddock S; McMahon FJ; Manji H; Lipsky RH
    Arch Gen Psychiatry; 2007 Jul; 64(7):783-92. PubMed ID: 17606812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.
    Athreya AP; Neavin D; Carrillo-Roa T; Skime M; Biernacka J; Frye MA; Rush AJ; Wang L; Binder EB; Iyer RK; Weinshilboum RM; Bobo WV
    Clin Pharmacol Ther; 2019 Oct; 106(4):855-865. PubMed ID: 31012492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SLC6A4 variation and citalopram response.
    Mrazek DA; Rush AJ; Biernacka JM; O'Kane DJ; Cunningham JM; Wieben ED; Schaid DJ; Drews MS; Courson VL; Snyder KA; Black JL; Weinshilboum RM
    Am J Med Genet B Neuropsychiatr Genet; 2009 Apr; 150B(3):341-51. PubMed ID: 18618621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram.
    Choi MJ; Kang RH; Ham BJ; Jeong HY; Lee MS
    Neuropsychobiology; 2005; 52(3):155-62. PubMed ID: 16127283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial.
    Lespérance F; Frasure-Smith N; Koszycki D; Laliberté MA; van Zyl LT; Baker B; Swenson JR; Ghatavi K; Abramson BL; Dorian P; Guertin MC;
    JAMA; 2007 Jan; 297(4):367-79. PubMed ID: 17244833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes.
    Mitjans M; Gastó C; Catalán R; Fañanás L; Arias B
    J Psychopharmacol; 2012 Oct; 26(10):1391-8. PubMed ID: 22826533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study.
    Zisook S; Trivedi MH; Warden D; Lebowitz B; Thase ME; Stewart JW; Moutier C; Fava M; Wisniewski SR; Luther J; Rush AJ
    J Affect Disord; 2009 Sep; 117(1-2):63-73. PubMed ID: 19217668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can Minnesota Multiphasic Personality Inventory-2 predict response to selective serotonin reuptake inhibitors in depressed outpatients?
    Kertzman S; Vainder M; Reznik I; Gotzlav Y; Weizman A; Kotler M; Iancu I
    Int Clin Psychopharmacol; 2012 May; 27(3):134-41. PubMed ID: 22415223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing effects of citalopram with fluoxetine on sleep quality in patients with major depressive disorder.
    Shahsavand-Ananloo E; Berenji F; Sadeghniiat K; Alimadadi A; Zahiroddin AR; Tabatabaee M; Abbasi-Asl M; Ghaeli P
    Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1155-61. PubMed ID: 23690183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response.
    Wade AG; Crawford GM; Nemeroff CB; Schatzberg AF; Schlaepfer T; McConnachie A; Haazen L; Buntinx E
    Psychol Med; 2011 Oct; 41(10):2089-97. PubMed ID: 21349239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
    Lam RW; Lönn SL; Despiégel N
    Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial.
    Williams LM; Korgaonkar MS; Song YC; Paton R; Eagles S; Goldstein-Piekarski A; Grieve SM; Harris AW; Usherwood T; Etkin A
    Neuropsychopharmacology; 2015 Sep; 40(10):2398-408. PubMed ID: 25824424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study.
    Eyre HA; Eskin A; Nelson SF; St Cyr NM; Siddarth P; Baune BT; Lavretsky H
    Int J Geriatr Psychiatry; 2016 May; 31(5):510-7. PubMed ID: 26471432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.